Drugs · acquisition-cost intelligence
haloperidol
· ingredient haloperidol· HALOPERIDOL 10 mg/1; HALOPERIDOL 5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.18012
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other haloperidol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| haloperidol | $0.12000 | −$0.06010 |
| haloperidol | $0.15824 | −$0.02190 |
| haloperidol | $0.16451 | −$0.01560 |
| Haloperidol | $0.47029 | +$0.29020 |
| Haloperidol | $0.77873 | +$0.59860 |
| Haloperidol | $0.77873 | +$0.59860 |
| Haldol Decanoate | $13.25 | +$13.07 |
| Haloperidol decanoate | $13.25 | +$13.07 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 13% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.